
Drip bars, immune support and recovery infusions, with NAD+ as the premium tier, built on protocols that hold up to scrutiny.
Book a Strategy CallIV therapy has moved from niche recovery treatment to mainstream consumer health. Monthly U.S. searches for IV therapy, IV hydration and IV drips each run 10,000 to 100,000 (Google Keyword Planner).
Entry barriers are lower here than in many categories: modest equipment, a straightforward menu and patients who already understand IV therapy.
ACG helps you launch a wellness clinic of your own, without the lifetime royalties of an IV therapy franchise.
IV therapy works as a standalone clinic and as an add-on for a longevity, hormone or aesthetics clinic, and can be an early source of cash flow.
Foundational drips to premium infusions, serving casual consumers and performance-focused patients from the same chair.
Myers' Cocktail, high-dose vitamin C, B-complex, and magnesium. The entry point for many new IV patients: high volume, fast turnaround, strong reorder rate.
Nicotinamide adenine dinucleotide, a high-ticket tier that complements foundational drips. It is compounded under FDA's interim policy for substances under evaluation; FDA proposed in 2019 not to add it to the 503A list, a rule not yet final.
High-dose vitamin C, zinc, and glutathione. Seasonal demand spikes create predictable high-volume windows.
Hydration, amino acid and electrolyte infusions for recovery after events or workouts, a natural partnership with gyms.
MIC injections, lipotropic blends and metabolic support infusions, a natural add-on for a medical weight loss clinic.
Licensed nurses deliver infusions to homes, offices and hotels, at premium prices and with lower fixed overhead. State rules on mobile administration vary.
EBOO, extracorporeal blood oxygenation and ozonation, comes up constantly, usually because a competitor advertises it or a vendor pitched it. We steer clients away from it, and would rather explain why than quietly leave it off the menu.
The FDA classifies ozone under 21 CFR 801.415 as a toxic gas with no known useful medical application. No ozone therapy device is FDA-approved. In July 2025 the agency issued a warning letter over the distribution of unapproved autohemotherapy and EBOO devices. EBOO is not FDA-approved for any condition and remains experimental.
A premium tier that rests on an unapproved device is not a differentiator. It is a liability with a price list attached.
The goal behind EBOO is usually a high-ticket premium tier. NAD+ already does that job with no unapproved device in the room, and high-dose vitamin C, glutathione and memberships fill out the premium end.
If you offer ozone anyway, that is your call and your Medical Director's. State positions vary, and neither ACG nor your marketing can claim what it treats.
Current as of October 2026. Verify with your Medical Director, your state board and qualified counsel before any clinical or equipment decision. ACG is a business consulting firm; this is not legal, medical, or regulatory advice.
From market review to opening day, ACG sets up what an IV clinic needs before its first patient.
Sterile preparation is where many IV clinics get caught: compounding standards, beyond-use dating and documentation turn a routine inspection into a problem.
Every IV service needs a licensed prescriber's order and medical oversight. ACG introduces vetted Medical Directors with IV experience, matched to your state and menu.
Who can start IVs, and what exam and supervision come first, varies by state; Texas and Maine tightened their rules in 2025 and 2026. ACG maps them for your location.
Every protocol is checked against its regulatory footing (approved, compoundable or off-label) before it is priced. Unapproved devices never make an ACG-built menu.
ACG connects clients to pre-vetted compounding pharmacy partners for custom IV formulations at preferred portfolio pricing.
Informed consent, patient-specific orders, emergency protocols and treatment documentation, structured to protect the clinic and meet state board requirements.
Patients return frequently: weekly hydration, monthly NAD+, seasonal immune support.
Under an Hour
A short intake and medical screening, then treatment. That simplicity drives volume.
High Retention
Monthly membership packages are designed to turn single visits into recurring revenue.
Independent MD
No medical background is required to own the business. An independent, state-licensed Medical Director directs all clinical care.
Launch Window
From keys received, market and regulatory conditions permitting.
Straight answers on staffing, costs, pricing and premium protocols, including the uncomfortable one. Anything else, ask on the strategy call.
View All FAQs
One of the quicker categories to launch. Talk with Grayson Miller about IV demand in your market, your menu and what opening takes. No pitch. No obligation.
ACG is a consulting and advisory firm, not a medical practice; an independent, state-licensed Medical Director directs all clinical care. Results are not guarantees of income. Individual outcomes vary. The 60-day target begins from clinic keys received, market and regulatory conditions permitting.
Knowing the rules is the foundation of every clinic we help launch.
You own and run the business. An independent, state-licensed Medical Director makes every clinical, prescribing and treatment decision, structured for your state's Corporate Practice of Medicine laws. We connect you to a vetted network; you retain your own provider.
PRP, peptides, GLP-1 medications and cellular products each carry federal and state rules, and not every product or use is FDA-approved. Exosomes for therapeutic use are not FDA-approved at all, and we steer you away from them. Your menu and marketing are built to hold up to FDA, FTC and state medical board scrutiny.
We show real ranges and never promise an income or a clinical outcome. What you earn depends on your market, your capital and your execution.
Altos Consulting Group is a business consulting and advisory firm, not a medical practice, and does not provide, prescribe or sell any drug, biologic, device or therapy. The FDA has stated there are currently no FDA-approved exosome products for the treatment of any disease; clinic owners are responsible for the compliance of every product, therapy and claim. See the full regulatory notice below.